PL2134685T3 - Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 - Google Patents

Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1

Info

Publication number
PL2134685T3
PL2134685T3 PL08745934T PL08745934T PL2134685T3 PL 2134685 T3 PL2134685 T3 PL 2134685T3 PL 08745934 T PL08745934 T PL 08745934T PL 08745934 T PL08745934 T PL 08745934T PL 2134685 T3 PL2134685 T3 PL 2134685T3
Authority
PL
Poland
Prior art keywords
nonsubstituted
mcl
inhibitors
indole derivatives
indole
Prior art date
Application number
PL08745934T
Other languages
English (en)
Inventor
Milan Bruncko
Xiaohong Song
Hong Ding
Zhi-Fu Tao
Aaron R Kunzer
Steven W Elmore
Cheol-Min Park
David Madar
Xilu Wang
Andrew J Souers
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PL2134685T3 publication Critical patent/PL2134685T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08745934T 2007-04-16 2008-04-16 Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 PL2134685T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91204907P 2007-04-16 2007-04-16
US94968307P 2007-07-13 2007-07-13
EP08745934.3A EP2134685B1 (en) 2007-04-16 2008-04-16 7-nonsubstituted indole derivatives as mcl-1 inhibitors
PCT/US2008/060427 WO2008130970A1 (en) 2007-04-16 2008-04-16 7-nonsubstituted indole mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
PL2134685T3 true PL2134685T3 (pl) 2016-02-29

Family

ID=39683700

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08745934T PL2134685T3 (pl) 2007-04-16 2008-04-16 Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1

Country Status (11)

Country Link
US (2) US7981888B2 (pl)
EP (1) EP2134685B1 (pl)
JP (2) JP5496876B2 (pl)
CN (1) CN101711235A (pl)
CA (2) CA2682354C (pl)
DK (1) DK2134685T3 (pl)
ES (1) ES2550753T3 (pl)
MX (1) MX2009011210A (pl)
PL (1) PL2134685T3 (pl)
PT (1) PT2134685E (pl)
WO (1) WO2008130970A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445679B2 (en) 2007-04-16 2013-05-21 Abbvie Inc. 7-substituted indole MCL-1 inhibitors
AU2009326259A1 (en) 2008-12-08 2011-07-28 Boehringer Ingelheim International Gmbh Compounds for treating cancer
JP5770102B2 (ja) * 2008-12-19 2015-08-26 ジェネンテック， インコーポレイテッド 複素環化合物と使用方法
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
EP3138838A1 (en) 2010-01-29 2017-03-08 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2567698B1 (en) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
EP2827864B1 (en) 2012-03-20 2020-09-30 Dana-Farber Cancer Institute, Inc. Inhibition of mcl-1 and/or bfl-1/a1
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
WO2015148854A1 (en) * 2014-03-27 2015-10-01 Vanderbilt University Substituted indole mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
CA2965173A1 (en) 2014-10-29 2016-05-06 The Walter And Eliza Hall Institute Of Medical Research Use of therapeutic agents
AU2016219183B2 (en) 2015-02-11 2020-06-11 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2016200726A1 (en) 2015-06-08 2016-12-15 Texas Tech University System Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
AU2016344118A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
AU2016344115A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
WO2017075178A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US11866409B2 (en) * 2015-11-02 2024-01-09 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
CN109153643B (zh) * 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
MX386103B (es) 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
CA3024482A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JP6910027B2 (ja) * 2017-03-29 2021-07-28 株式会社コーセー チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白剤
US20200062738A1 (en) * 2017-04-30 2020-02-27 Development Center For Biotechnology Anti-cancer stemness drugs
TWI810220B (zh) 2017-11-17 2023-08-01 德商拜耳廠股份有限公司 經取代之巨環吲哚衍生物
UY37973A (es) 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos
WO2019096909A1 (en) 2017-11-17 2019-05-23 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
US11478451B1 (en) 2017-11-17 2022-10-25 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096914A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096907A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
JP2022503896A (ja) * 2018-09-30 2022-01-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド インドール大環状誘導体、その調製方法、及びその医薬への応用
US11691989B2 (en) * 2018-11-22 2023-07-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as Mcl-1 inhibitors
US12338250B2 (en) 2019-05-17 2025-06-24 The Broad Institute, Inc. Methods of preparing macrocyclic indoles
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021099579A1 (en) 2019-11-21 2021-05-27 Janssen Pharmaceutica Nv Macrocyclic indole derivatives as mcl-1 inhibitors
MX2022006180A (es) 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
WO2021107125A1 (ja) 2019-11-29 2021-06-03 小野薬品工業株式会社 リゾホスファチジン酸受容体作動活性を有する化合物およびその医薬用途
TW202144368A (zh) * 2020-03-30 2021-12-01 大陸商江蘇恒瑞醫藥股份有限公司 吲哚類大環衍生物的結晶形式及其製備方法
EP4157852A1 (en) 2020-05-29 2023-04-05 JANSSEN Pharmaceutica NV Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
WO2021255257A1 (en) 2020-06-19 2021-12-23 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632805A (en) 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
FR2187318B1 (pl) 1972-06-08 1975-06-20 Delalande Sa
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
KR100482268B1 (ko) * 1996-08-01 2005-04-14 메르클레 게엠베하 세포질 포스포리파제 ａ2의 저해제로서의 아실피롤디카르복실산
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
EP1359138B1 (en) 1998-11-27 2006-02-08 Mitsubishi Chemical Corporation Process for the production of maleic anhydride
GB9902452D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000626D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
HUP0302477A2 (hu) * 2000-10-10 2003-12-29 Smithkline Beecham Corp. Szubsztituált indolszármazékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása PPAR-gamma kötő szerként
DE10153346A1 (de) * 2001-10-29 2004-04-22 Grünenthal GmbH Substituierte Indole
EP1456165A1 (en) 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003239150A1 (en) 2002-04-23 2003-11-10 Aventis Pharmaceuticals Inc. 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
AU2004215428B2 (en) * 2003-02-26 2009-08-27 Sugen LLC Aminoheteroaryl compounds as protein kinase inhibitors
US7141600B2 (en) * 2003-04-15 2006-11-28 The Regents Of The University Of California Small molecule inhibition of a PDZ-domain interaction
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
DE602005009209D1 (de) * 2004-06-18 2008-10-02 Biolipox Ab Zur behandlung von entzündungen geeignete indole
RU2007101703A (ru) * 2004-06-18 2008-07-27 Биолипокс Аб (Se) Индолы, полезные при лечении воспаления
US20080146616A1 (en) * 2004-06-18 2008-06-19 Kristofer Olofsson Indoles Useful in the Treatment of Inflammation
WO2006041961A1 (en) * 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
ZA200705827B (en) * 2005-01-19 2008-10-29 Biolipox Ab Indoles useful in the treatment of inflammation
CA2594777A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
JP5193861B2 (ja) * 2005-07-07 2013-05-08 アボット・ラボラトリーズ アポトーシス促進剤
PE20080767A1 (es) * 2006-08-31 2008-08-08 Smithkline Beecham Corp Derivados de acido 1-indol-2-carboxilico como moduladores de ppar
US8445679B2 (en) * 2007-04-16 2013-05-21 Abbvie Inc. 7-substituted indole MCL-1 inhibitors
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
JP5770102B2 (ja) 2008-12-19 2015-08-26 ジェネンテック， インコーポレイテッド 複素環化合物と使用方法

Also Published As

Publication number Publication date
PT2134685E (pt) 2015-11-25
CA2682354C (en) 2016-12-13
JP2010524955A (ja) 2010-07-22
US7981888B2 (en) 2011-07-19
DK2134685T3 (en) 2015-12-07
CN101711235A (zh) 2010-05-19
EP2134685B1 (en) 2015-09-02
US20090124616A1 (en) 2009-05-14
WO2008130970A1 (en) 2008-10-30
JP5895011B2 (ja) 2016-03-30
MX2009011210A (es) 2009-10-30
JP5496876B2 (ja) 2014-05-21
CA2951295A1 (en) 2008-10-30
CA2682354A1 (en) 2008-10-30
CA2951295C (en) 2020-04-28
US20110263599A1 (en) 2011-10-27
US8853209B2 (en) 2014-10-07
ES2550753T3 (es) 2015-11-12
JP2014129396A (ja) 2014-07-10
EP2134685A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
PT2134685E (pt) Derivados de índole não substituídos na posição 7 como inibidores de mcl-1
IL201432A0 (en) 7 - substituted indole mcl - 1 inhibitors
ZA200904138B (en) Substituted spirochromanone derivatives as acc inhibitors
IL207684A0 (en) Substituted indole derivatives
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
PL2215075T3 (pl) Pochodne chinolinonu jako inhibitory PARP
ZA201104361B (en) Substituted dioxopiperidinyl phthalimide derivatives
IL202020A0 (en) Spiroindolinone derivatives
IL208203A0 (en) Heterocyclic derivatives
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
GB0905328D0 (en) Indole derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
AP2743A (en) Macrocyclic indole derivatives useful as hepatitisC virus inhibitors
IL202034A0 (en) Heterocyclic indazole derivatives
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
IL211290A0 (en) New 2-amidothiadiazole derivatives
IL202612A0 (en) Compositions comprising tryptophan hydroxylase inhibitors
IL207225A0 (en) Indazole derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA200905265B (en) Indole derivatives
ZA201002580B (en) Heterocyclic derivatives